• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day

    4/22/25 8:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email
    • National Parvo Awareness Day raises awareness of canine parvovirus (parvo), the often-fatal puppy disease.
    • Elanco's Canine Parvovirus Monoclonal Antibody (CPMA) is the first-and-only USDA conditionally approved treatment for parvo.
    • Puppies treated with CPMA had a 93% survival rate and returned home an average of 1.87 days sooner.1,2
    • Elanco's ParvoTrack, the first-ever national online parvo tracking tool, allows pet owners and veterinarians to self-report outbreaks in real time, further highlighting the need for CPMA across the country and reinforcing Elanco's commitment to increasing the availability of CPMA.
    • Texas, Arizona, Georgia, Florida, Illinois, Indiana and New York have some of the highest reported cases of canine parvovirus outbreaks according to ParvoTrack.

    GREENFIELD, Ind., April 22, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today recognizes the second annual National Parvo Awareness Day, aimed at increasing awareness of canine parvovirus, a highly contagious and often-fatal puppy disease. Since receiving conditional approval from the USDA, Canine Parvovirus Monoclonal Antibody (CPMA) has helped save thousands of puppies.3 Although parvovirus can strike anytime, late spring and summer months are the most common for outbreaks nationwide.

    Experience the full interactive Multichannel News Release here: https://www.multivu.com/elanco/9306451-en-elanco-animal-health-second-annual-national-parvo-awareness-day

    "Parvo is a devastating disease that not only impacts our pets, but takes an emotional toll on pet owners, veterinarians and animal health experts," said Dr. Chris George, veterinarian and infectious disease expert at Elanco Animal Health. "Without supportive care, parvo has a 91% mortality rate.4 However, there's a treatment beyond just supportive care – Elanco's CPMA which can help defend puppies and defeat parvo. In real-world usage, 93% of parvo-infected puppies treated with CPMA survived.1 Additionally, parvo patients treated with CPMA spend an average of 1.87 less days in the hospital, helping to relieve the emotional toll on treating veterinary staff and getting pets back with their families. CPMA is changing the way we treat parvo and is helping save puppies across the country."2

    Elanco's mission to save 1 million puppies from parvovirus by 2030

    "Making CPMA widely available is crucial in our fight against this devastating virus, including in shelter environments where resources are often strained," said Bobby Modi, Executive Vice President, U.S. Pet Health. "Elanco is focused on increasing access to this life-saving treatment, and we've saved thousands of puppies in the first year3 – but we need help from every clinic around the country to reach our mission of saving 1 million puppies from parvovirus by 2030. We believe every clinic and shelter should experience the power of CPMA firsthand, so we encourage clinics who haven't tried it to learn more about how they can save their first parvo puppy using CPMA."

    Last year, Elanco launched ParvoTrack as the first-ever real-time online parvo tracking tool, empowering pet owners and the veterinary community with innovative intelligence to help notify them of parvo outbreaks in their communities. Visitors to the site can self-report and identify parvo outbreak areas, with a few simple steps, as well as sign up for parvo outbreak alerts in their area. Since launching ParvoTrack last year, thousands of parvo cases have been reported nationwide, with over 7,000 pet owners and veterinarians signing up to receive alerts with outbreaks in their area. ParvoTrack updates in real time and displays data from the past 12 months. Parvo outbreaks have occurred in every state with Texas, Arizona, Georgia, Florida, Illinois, Indiana and New York having some of the highest reported cases of canine parvovirus outbreaks.

    "Every clinic and every shelter should have CPMA readily available."

    "We've been treating parvo since early 2020 and it can be an absolutely devastating disease that weighs heavily on the staff," said Dr. Meghan Herron, Senior Director of Behavior, Research, and Education at Gigi's, an Ohio-based organization dedicated to improving the lives of shelter dogs. "Now that we have CPMA on board, everyone's attitudes have changed. We no longer must fear a parvo outbreak because we have a treatment on hand that reduces hospitalization time and has a 93% survival rate. Every clinic and every shelter should have CPMA readily available."

    Survivor Stories

    Here are just a few of the faces that fully recovered from parvovirus after receiving lifesaving CPMA treatment.

    Cookie, an 8-week-old pitbull mix puppy from California, was the first puppy to be treated with CPMA.

    Dolly, an 8-week-old mixed breed puppy from Sugar Land, Texas received CPMA at the First Colony Veterinary Clinic.

    Patrick, a 10-week-old terrier mix from Valley Stream, New York spent two days at BARRK Animal Rescue after being treated with CPMA.

    Beatrix, a 3-month-old dalmatian from Glendale, Arizona.

    Buster, a 12-week-old mixed breed from Waynesboro, Georgia spent four days in the Burke County Animal Hospital.

    Luna, a 10-week-old rat terrier from St. Petersburg, Florida was given CPMA and after receiving the treatment, was eating, gaining weight and steadily improving. Two days later, she made a full recovery.

    Similarly, Mono, a 2-month-old mixed breed who arrived at Paws Chicago after staff was told he required immediate help or face euthanasia; Mono tested positive for parvo and immediately received CPMA. Three days post-treatment, he was up running around.

    To learn more about CPMA and report a parvo outbreak or learn which clinics near you carry CPMA, visit ParvoTrack.com.

    Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

    ©2025 Elanco or its affiliates. PM-US-25-0730

    ABOUT ELANCO

    Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.

    1 Elanco Animal Health. Market Data on File.

    2 Elanco Animal Health. Industry Data on File.

    3 Elanco Animal Health. Data on File.

    4 Sykes, JE. Canine Parvovirus Infections and Other Viral Enteritides. Canine and Feline Infectious Diseases. 2014:141-151

    Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected]

    Media Contact: Season Solorio (765) 316-0233 [email protected]

     

    Mono, a 2-month-old mixed breed, was treated at Paws Chicago after staff were told he required immediate help or face euthanasia. Mono tested positive for parvo and immediately received CPMA. Three days post-treatment, he was up running around.

     

    Elanco logo

     

    Cision View original content:https://www.prnewswire.com/news-releases/elancos-breakthrough-treatment-for-deadly-canine-parvovirus-has-saved-thousands-of-puppies-reaffirms-commitment-to-increasing-the-availability-of-canine-parvovirus-monoclonal-antibody-for-second-annual-national-parvo-awareness-d-302433859.html

    SOURCE Elanco Animal Health

    Get the next $ELAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    1/22/2026Neutral → Overweight
    Piper Sandler
    12/9/2025$30.00Overweight
    Barclays
    11/21/2025$27.00Overweight
    KeyBanc Capital Markets
    11/19/2025$25.00Hold → Buy
    Argus
    10/7/2025$24.00Neutral → Overweight
    Analyst
    7/17/2025$18.00Market Perform → Outperform
    Leerink Partners
    6/26/2025Mkt Perform → Outperform
    William Blair
    12/9/2024$18.00Buy
    UBS
    More analyst ratings

    $ELAN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Elanco Animal Health Incorporated

    SCHEDULE 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    3/26/26 6:05:56 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Elanco Animal Health Incorporated

    10-K - Elanco Animal Health Inc (0001739104) (Filer)

    2/24/26 9:19:48 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Elanco Animal Health Inc (0001739104) (Filer)

    2/24/26 6:28:19 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/24/26 4:43:49 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/24/26 4:43:15 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Vanhimbergen Robert M

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/24/26 4:31:49 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results

    Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day OutlookFourth Quarter 2025 Financial Results:Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currencyReported Net Loss of $276 million, Adjusted Net Income of $64 millionAdjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7%Reported EPS of $(0.56), Adjusted EPS of $0.13Full Year 2025 Financial Results:Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025Revenue of $4,715 million, incre

    2/24/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco to Participate in Upcoming Investor Conferences

    INDIANAPOLIS, Ind., Feb. 19, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that management will participate in upcoming investor conferences. On Thursday, February 26, Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will participate in a fireside chat at the BofA 2026 Animal Health Summit at 11:35 a.m. ET.On Monday, March 2, Bob VanHimbergen, executive vice president and CFO, and Luke Smith, vice president and CFO – US Pet Health, US Farm Animal, and Global Manufacturing, will participate in a fireside

    2/19/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Announces Updates to Board of Directors

    INDIANAPOLIS, Feb. 13, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced updates to its Board of Directors. R. David Hoover and Deborah Kochevar will not stand for re-election at the conclusion of their terms at the 2026 Annual Meeting of Shareholders in May. Mr. Hoover is retiring from his role after joining the Board in September of 2018 as the first Chairman of the Board at the time of the company's IPO. Dr. Kochevar joined in March of 2019 as the company completed its separation from Eli Lilly and Company. "Dave Hoover's leadership was abso

    2/13/26 9:24:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $478,496 worth of shares (22,000 units at $21.75) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:41:24 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Modi Rajeev A. bought $95,985 worth of shares (4,500 units at $21.33), increasing direct ownership by 4% to 123,082 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:43:23 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elanco Animal Health upgraded by Piper Sandler

    Piper Sandler upgraded Elanco Animal Health from Neutral to Overweight

    1/22/26 8:20:23 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Elanco Animal Health with a new price target

    Barclays initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $30.00

    12/9/25 8:46:01 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KeyBanc Capital Markets initiated coverage on Elanco Animal Health with a new price target

    KeyBanc Capital Markets initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $27.00

    11/21/25 8:08:36 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Financials

    Live finance-specific insights

    View All

    Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results

    Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day OutlookFourth Quarter 2025 Financial Results:Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currencyReported Net Loss of $276 million, Adjusted Net Income of $64 millionAdjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7%Reported EPS of $(0.56), Adjusted EPS of $0.13Full Year 2025 Financial Results:Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025Revenue of $4,715 million, incre

    2/24/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement

    INDIANAPOLIS, Jan. 22, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. Eastern Standard Time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-

    1/22/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Investor Day Defines New Era as Sustainable Growth Company

    Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to <3x in 2027, with a long-term target of 2.0x to 2.5x.Expects innovation revenue contribution of approximately $1.1 billion in 2026, with aims to double revenue from 'Big 6' blockbuster potential products by 2028.Discusses 10+ major innovation products in development phase with 5-6 blockbuster-potential approvals expected between 2026 and 2031. Two in-house technology development platforms

    12/9/25 7:40:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    7/8/24 4:32:39 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/13/24 2:08:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/12/24 4:01:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Leadership Updates

    Live Leadership Updates

    View All

    Elanco executive appointed as Neurizon's Board Observer

    MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited ((ASX: NUZ &, NUZOA, OTCQB:NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE:ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative. The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. The appointment follo

    11/26/25 6:15:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    Banks
    Finance
    Savings Institutions
    Biotechnology: Pharmaceutical Preparations

    Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

    The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

    6/5/25 7:45:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care